Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill shows promise for controlling stubborn eczema in real life

NCT ID NCT05689151

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 4 times

Summary

This study is tracking 183 adults with moderate-to-severe atopic dermatitis (eczema) who are taking abrocitinib, a daily tablet. Researchers want to see how well the drug works in real-life settings, not just in controlled clinical trials. Participants will be followed for 24 months with about 5 clinic visits to check skin improvement and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abrocitinib (a daily tablet)
What this could lead to
If successful, this study could confirm that abrocitinib is a safe and effective option for controlling moderate-to-severe eczema in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It also only follows patients for 24 months, so long-term effects remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 183 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of moderate to severe atopic dermatitis for whom the dermatologist has decided to initiate a treatment with Abrocitinib

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years of age at inclusion. * Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval. * Patients that have been informed of the study procedures and have signed the consent. Exclusion Criteria: * Patients for whom abrocitinib is contraindicated. * Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons. * Patients not affiliated to the French social security system. * Patients deprived of liberty, under guardianship, or unable to provide oral consent. * Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Eczema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH de Martigues

    RECRUITING

    Martigues, 13698, France

  • CHU Amiens-Picardie - Site Nord

    RECRUITING

    Amiens, Somme, 80080, France

  • CHU Besancon - Hopital Jean Minjoz

    RECRUITING

    Besançon, 25000, France

  • CHU Brest Hopital Morvan

    RECRUITING

    Brest, 29609, France

  • CHU Clermont Ferrand - Hopital Gabriel Montpied

    RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU Lyon Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • CHU Montpellier

    RECRUITING

    Montpellier, 34295, France

  • CHU Nancy

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

  • CHU de Caen

    RECRUITING

    Caen, 14033, France

  • Ch William Morey

    RECRUITING

    Chalon-sur-Saône, 71100, France

  • Ch de Calais

    RECRUITING

    Calais, 62107, France

  • Ch de Romans Sur Isere

    RECRUITING

    Romans-sur-Isère, 26102, France

  • Ch de Valenciennes

    RECRUITING

    Valenciennes, 59322, France

  • Chi Poissy Saint Germain En Laye

    RECRUITING

    Saint-Germain-en-Laye, 78105, France

  • Chu Bordeaux Hopital Saint Andre

    RECRUITING

    Bordeaux, 33075, France

  • Chu Dijon

    RECRUITING

    Dijon, 21000, France

  • Chu Estaing

    RECRUITING

    Clermont-Ferrand, 63003, France

  • Hopital Bégin

    RECRUITING

    Saint-Mandé, 94160, France

  • Hopital Charles Nicolle

    RECRUITING

    Rouen, 76031, France

  • Hopital Claude Huriez

    RECRUITING

    Lille, 59000, France

  • Hopital Cochin

    RECRUITING

    Paris, 75014, France

  • Hopital Emile Muller

    RECRUITING

    Mulhouse, 68070, France

  • Hopital Franco Britannique

    RECRUITING

    Levallois-Perret, 92300, France

  • Hopital Henri Mondor

    RECRUITING

    Créteil, 94010, France

  • Hopital Hotel Dieu

    RECRUITING

    Nantes, 44000, France

  • Hopital Larrey

    RECRUITING

    Toulouse, 31000, France

  • Hopital Pontchaillou

    RECRUITING

    Rennes, 35033, France

  • Hopital Saint Louis (APHP) - Service Hematologic Senior

    RECRUITING

    Paris, 75475, France

  • Hopital Tenon

    RECRUITING

    Paris, 75020, France

  • Polyclinique Reims Bezannes

    RECRUITING

    Bezannes, 51430, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.